The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity

Anticancer Res. 1992 Nov-Dec;12(6B):1925-33.

Abstract

The effects of an anti-CD3 mAb on induction of non-MHC restricted cytolysis was investigated. Peripheral blood mononuclear cells (PBMC) from normal donors (29) and cancer patients (18) were cultured in 100 U/ml of interleukin-2 (rIL-2) with and without anti-CD3 mAb (OKT3, 10 ng/ml) for the first 48 hours of incubation. Thereafter, both PBMC cultures were maintained on rIL-2 up to 20 days. PBMC proliferation was enhanced 17-fold in number by day 20 when anti-CD3 mAb and rIL-2 was present during the first 48 hours but only 3-fold by day 20 when rIL-2 alone was present. Concomitantly anti-CD3 mAb but not Lym-1, an isotype matched control, inhibited the induction of lytic activity against both NK sensitive (K562) and NK resistant (Raji) target cell lines. Thus the inhibitory effect is dependent on anti-CD3 mAb stimulating the CD3/TCR T-cell receptor complex. While lytic activity was dependent on the concentration of rIL-2, inhibition of the induction phase of non-MHC restricted lytic activity was independent of the concentration of rIL-2. Flow cytometry analysis indicated that treatment with the anti-CD3 mAb increased the percentage of CD3 positive cells, CD4 positive cells and especially CD25 positive cells, but decreased th percentage of CD56 positive cells. Supernatants from anti-CD3 mAb stimulated cultures also inhibited the induction of non-MHC restricted lytic activity. Lymphokine analysis showed that supernatants of anti-CD3 mAb stimulated cultures had higher levels of TNF-alpha and IFN-gamma. However, TNF-alpha and IFN-gamma alone or in combination could not mediate the inhibitory effect. The inhibitory factor(s) was partially purified by sequential chromatography on matrices of controlled pore glass and Sepharose CL-6B. The molecular weight of the inhibitory factor(s) was less than 67K. These studies have identified a novel regulatory pathway controlling non-MHC restricted cytolysis. Perturbation of the T-cell CD3/TCR complex with the anti-CD3 mAb results in the secretion of a soluble mediator that down-regulates the induction of rIL-2 dependent non-MHC restricted cytolysis.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / pharmacology*
  • CD3 Complex / immunology*
  • Carcinoma, Renal Cell / blood
  • Carcinoma, Renal Cell / immunology
  • Cells, Cultured
  • Cytotoxicity, Immunologic*
  • Flow Cytometry
  • Humans
  • Interferon-gamma / pharmacology
  • Interleukin-2 / pharmacology
  • Killer Cells, Lymphokine-Activated / drug effects
  • Killer Cells, Lymphokine-Activated / immunology*
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / immunology*
  • Kinetics
  • Lung Neoplasms / blood
  • Lung Neoplasms / immunology
  • Lymphocyte Activation*
  • Lymphocytes / drug effects
  • Lymphocytes / immunology*
  • Lymphokines / biosynthesis
  • Lymphoma / blood
  • Lymphoma / immunology
  • Major Histocompatibility Complex
  • Melanoma / blood
  • Melanoma / immunology
  • Middle Aged
  • Neoplasms / immunology*
  • Recombinant Proteins
  • Reference Values
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Antibodies, Monoclonal
  • CD3 Complex
  • Interleukin-2
  • Lymphokines
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Interferon-gamma